- ENDV
has developed a viable pain-control solution for those seeking
alternatives to highly addictive opioids
- The
company’s flagship product is an FDA-cleared, easy-to-place, noninvasive
device that delivers pulsed electromagnetic frequencies to targeted area
- In one
study, patients treated with Endonovo technology reported a decrease
in pain medication by nearly threefold
Amid mounting concern about the alarming opioid-addiction
crisis, Endonovo Therapeutics Inc. (OTCQB: ENDV) offers one of
the few bright spots on the horizon. Endonovo is the commercial-stage developer
of noninvasive Electroceutical(TM) Therapeutic devices designed to target
patient pain and inflammation, a viable pain-control solution for those
desperately seeking options other than highly addictive drugs.
The crisis is real. The National Institute on Drug Abuse
reports that 21% to 29% of patients prescribed opioids for chronic pain misuse
them, and more than 130 people in the United States die every day after
overdosing on opioids (http://ibn.fm/92SUO).
The economic burden of the crisis is also heavy, with prescription opioid
misuse alone in the United States totaling $78.5 billion annually including the
costs of health care, lost productivity, addiction treatment and criminal justice
involvement.
Endonovo provides an alternative. The company’s flagship
product, SofPulse(R) Electroceutical(TM) Therapy is an FDA-cleared,
easy-to-place, noninvasive device that delivers targeted pulsed electromagnetic
field (tPEMF) frequencies to enhance postsurgical recovery. Used as a
standalone therapy or integrated into any treatment protocol,
SofPulse transmits gentle pulses to the tissue causing a positive biological
effect to help reduce swelling and accelerate the body’s natural recovery process.
Patients using SofPulse require significantly fewer prescription medications,
potentially decreasing the adverse side effects of opioid medication.
Endonovo’s tPEMF technology is FDA approved for the
treatment of post-operative pain and edema, with studies indicating that the
technology is at least as effective as NSAIDs in the treatment of pain and
swelling. In one study, patients treated with Endonovo tPEMF technology
experienced a decrease in pain medication by nearly threefold compared to those
who didn’t receive the therapy (http://ibn.fm/jkeC1).
Battery-operated and disposable, SofPulse(R) is a wearable
device that delivers electromagnetic pulses either manually or in a
preprogrammed mode that automatically provides 15 minutes of therapy every two
hours. The pulses go through dressings, casts and clothing, and the convenient
device allows a person to remain mobile while still receiving powerful
treatment. The treatment can also be integrated into a variety of
pain-management, wound-care and post-op protocols.
Endonovo is focused on providing clinical solutions
substantiated with research and evidence-based data. The company also strives
to be an educational resource for clinicians and has created a research library
comprised of the latest clinical data, abstracts and media that focuses on
tPEMF technologies. Based on the company’s key technological developments and
innovative therapies, Endonovo may represent a significant long-term valuation
potential.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment